A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer

Summary

-Interventional trials aim at preventing severe RIF occurrence in BC patients selected by individual radiosensitivity: PRAVAPREV-01 will be the first interventional double blind trial that will offer a personalised strategy to breast cancer patients who will be treated with adjuvant RT after breast conserving surgery: * By assessing individual risk of severe RIF development * By offering a statin targeted therapy to the high-risk patients identified.

Timeline

Start

2020-12-04

Primary completion

2023-04-27

Completion

2023-04-27

Drugs

Indications